Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 43.70% is 118% above its 5-year average of -237.59%, near the high end of its 5-year range (-670.56%–83.23%).
112.42% above its 12-month average of -351.75%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -339.62%.
EBITDA MARGIN
43.70%
EBITDA MARGIN AVG TTM
-351.75%
EBITDA MARGIN AVG 3Y
-267.06%
EBITDA MARGIN AVG 5Y
-237.59%
EBITDA MARGIN AVG 10Y
-223.15%
EBITDA MARGIN AVG 15Y
-675.55%
EBITDA MARGIN AVG 20Y
-806.57%
CURRENT VS TTM AVG
+112.42%
CURRENT VS 3Y AVG
+116.36%
CURRENT VS 5Y AVG
+118.39%
CURRENT VS 10Y AVG
+119.58%
CURRENT VS 15Y AVG
+106.47%
CURRENT VS 20Y AVG
+105.42%
Compugen Ltd.
Market Cap
$218.42M
EBITDA Margin
43.70%
TTM Avg
-351.75%
3Y Avg
-267.06%
5Y Avg
-237.59%
Market Cap
$220.94M
EBITDA Margin
-646.93%
TTM Avg
-391.16%
3Y Avg
-256.59%
5Y Avg
-321.84%
Market Cap
$236.56M
EBITDA Margin
-25.05%
TTM Avg
-32.88%
3Y Avg
-63.97%
5Y Avg
-61.52%
Market Cap
$239.45M
EBITDA Margin
-1029.09%
TTM Avg
-1029.09%
3Y Avg
-1029.09%
5Y Avg
-1029.09%
Market Cap
$192.97M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$244.25M
EBITDA Margin
10.49%
TTM Avg
1.20%
3Y Avg
-4.19%
5Y Avg
-40.04%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Compugen Ltd. (CGEN) | $218.42M | 43.70% | -351.75% | -267.06% | -237.59% |
| Alector, Inc. (ALEC)vs › | $220.94M | -646.93% | -391.16% | -256.59% | -321.84% |
| Electra Therapeutics Inc. (ETRA)vs › | $206.61M | N/A | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $202.05M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $236.56M | -25.05% | -32.88% | -63.97% | -61.52% |
| BioAge Labs Inc. (BIOA)vs › | $239.45M | -1029.09% | -1029.09% | -1029.09% | -1029.09% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $244.25M | 10.49% | 1.20% | -4.19% | -40.04% |
| Galectin Therapeutics Inc. (GALT)vs › | $245.65M | N/A | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $248.21M | N/A | N/A | N/A | N/A |
Gross Margin
86.9%
EBITDA Margin
43.7%
Operating Margin
40.9%
Net Margin
47.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -339.62% |
| 2026-03-31 | -414.38% |
| 2025-12-31 | 83.23% |
| 2025-09-30 | -417.40% |
| 2025-06-30 | -670.56% |
| 2025-03-31 | -367.56% |
| 2024-12-31 | -508.70% |
| 2024-09-30 | 26.24% |
| 2024-06-30 | -50.91% |
| 2024-03-31 | -331.85% |
| 2023-12-31 | 53.88% |
| 2022-12-31 | -46.33% |
| 2021-09-30 | -104.65% |
| 2020-12-31 | -440.20% |
| 2018-09-30 | -42.72% |
| 2018-03-31 | 1.15% |
| 2016-12-31 | -16484.91% |
| 2016-09-30 | -11381.43% |
| 2016-06-30 | -1271.77% |
| 2016-03-31 | -9538.71% |
| 2015-12-31 | -1.17% |
| 2015-09-30 | -3019.21% |
| 2015-06-30 | -2902.69% |
| 2015-03-31 | -1232.36% |
| 2014-12-31 | -10.91% |
| 2014-09-30 | -267.35% |
| 2014-06-30 | -155.70% |
| 2014-03-31 | -155.23% |
| 2013-12-31 | -215.66% |
| 2013-09-30 | -276.86% |
| 2013-06-30 | -20359.09% |
| 2013-03-31 | -2446.91% |
| 2012-12-31 | -2727.61% |
| 2012-09-30 | -3355.56% |
| 2011-12-31 | 667.45% |
| 2010-12-31 | -1184.21% |
| 2010-06-30 | -117.12% |
| 2010-03-31 | -2174.40% |
| 2009-12-31 | -7756.00% |
| 2008-12-31 | -28709.09% |
| 2007-12-31 | -3812.22% |
| 2006-03-31 | -1597.00% |
| 2005-09-30 | -451.12% |
| 2004-09-30 | -364.47% |
| 2004-06-30 | -376.63% |
| 2004-03-31 | -217.43% |
| 2003-12-31 | -336.08% |
| 2003-09-30 | -155.64% |
| 2003-06-30 | -97.24% |
| 2003-03-31 | -114.45% |
| 2002-09-30 | -126.65% |
